The role of matrix metalloproteinases in acute coronary syndromes

European Journal of Internal Medicine

Volumn 18, Issue 6, 2007, Pages 463-466

  Dabek, Jozefa ^a   Kulach, Andrzej ^a   Gasior, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute coronary syndrome; Matrix metalloproteinases; MMP; Myocardial infarction

Indexed keywords

MATRIX METALLOPROTEINASE;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARCINOGENESIS; CARDIOVASCULAR SYSTEM; CONNECTIVE TISSUE; DEGENERATIVE DISEASE; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME REGULATION; HEALING; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; LEARNING; PATHOLOGY; PHYSIOLOGY; REVIEW; TURNOVER TIME;

EID: 34548477674     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.01.007     Document Type: Review

References (34)

1. Barrett A.J., Rawlings N.D., and Woessner J.F. Handbook of proteolytic enzymes (1998), Academic Press, London
2. Toy L.W. Matrix metalloproteinases: their function in tissue repair. J Wound Care 14 (2005) 20-22
3. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9 (2005) 267-285
4. Kazes I., Elalamy I., Sraer J.D., Hatmi M., and Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 96 (2000) 3064-3069
5. Vu T.H., and Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14 (2000) 2123-2133
6. Vihinen P., and Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99 (2002) 157-166
7. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
8. Hanemaaijer R., Koolwijk P., le Clercq L., de Vree W.J., and van Hinsbergh V.W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumor necrosis factor α, interleukin 1 and phorbol ester. Biochem J 296 (1993) 803-809
9. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75 (1994) 181-189
10. Coker M.S., Thomas C.V., and Doscher M.A. Matrix metalloproteinase expression and activity in adult ventricular myocytes: influence of basement membrane adhesion. Circulation 96 s.1 (1997) I-689
11. Pollanen P.J., Karhunen P.J., Mikkelsson J., Laippala P., Perola M., Penttila A., et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol 21 9 (Sep 2001) 1446-1450
12. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 14 (Apr 13 1999) 1788-1794
13. Yakubenko V.P., Lobb R.R., Plow E.F., and Ugarova T.P. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res 260 (2000) 73-84
14. Aoudjit F., Potworowski E.F., and St-Pierre Y. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. J Immunol 160 (1998) 2967-2973
15. Vincenti M.P. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 151 (2001) 121-148
16. Schonbeck U., Mach F., Sukhova G.-K., Murphy C., Bonnefoy J.Y., Fabunmi R.P., et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?. Circ Res 81 (1997) 448-454
17. Spiegel S., Foster D., and Kolesnick R. Signal transduction through lipid second messengers. Curr Opin Cell Biol 8 (1996) 159-167
18. Fabunmi R.P., Baker A.H., Murray E.J., Booth R.F., and Newby A.C. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J 315 (1996) 335-342
19. Kameda K., Matsunaga T., Abe N., Hanada H., Ishizaka H., Ono H., et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 24 (2003) 2180-2185
20. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
21. Katsuda S., and Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 10 (2003) 267-274
22. Kalela A., Koivu T.A., Sisto T., Kanervisto J., Hoyhtya M., Sillanaukee P., et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 62 (2002) 337-342
23. Pasterkamp G., Schoneveld A.H., Hijnen D.J., de Kleijn D.P., Teepen H., van der Wal A.C., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150 (2000) 245-253
24. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
25. Sawicki G., Salas E., Murat J., Miszta-Lane H., and Radomski M.W. Release of gelatinase A during platelet activation mediates aggregation. Nature 386 (1997) 616-619
26. Sato S., Ashraf M., Millard R.W., Fujiwara H., and Schwartz A. Connective tissue changes in early ischemia of porcine myocardium: an ultrastructural study. J Mol Cell Cardiol 15 (1983) 261-275
27. Herzog E., Gu A., Kohmoto T., Burkhoff D., and Hochman J.S. Early activation of metalloproteinases after experimental myocardial infarction occurs in infarct and non-infarct zones. Cardiovasc Pathol 7 (1998) 307-312
28. Danielsen C.C., Wiggers H., and Andersen H.R. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 30 (1998) 1431-1442
29. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevent cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 10 (1999) 1135-1142
30. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
31. De B., Natchus M.G., Cheng M., Pikul S., Almstead N.G., Taiwo Y.O., et al. The next generation of MMP inhibitors. Design and synthesis. Ann N Y Acad Sci 878 (1999) 40-60
32. Belotti D., Paganoni P., and Giavazzi R. MMP inhibitors: experimental and clinical studies. Int J Biol Markers 14 (1999) 232-238
33. Tziakas D.N., Chalikias G.K., Parissis J.T., Hatzinikolaou E.I., Papadopoulos E.D., Tripsiannis G.A., et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 94 2-3 (Apr 2004) 269-277
34. Arikan M.C., Shapiro S.D., and Mariani T.J. Induction of macrophage elastase (MMP-12) gene expression by statins. J Cell Physiol 204 1 (Jul 2005) 139-145